Adnan M. Nagrial
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adnan M. Nagrial has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Venessa Chin
Translational Genomics Program, Garvan Institute of Medical Research, Sydney, Australia
3 shared publications - Andrew Victor Biankin
Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow
2 shared publications - Desmond Yip
Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia
2 shared publications - Katrin Sjoquist
NHMRC Clinical Trials Centre, University of Sydney, 119-143 Missenden Rd, Sydney, NSW 2050, Australia
2 shared publications - Marina Pajic
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia
2 shared publications - Adrienne Morey
Anatomical Pathology, Sydpath, St Vincent’s Hospital, Sydney, Australia
1 shared publication
Latest Publications
- 1 December 2015
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 96 (3) , 483-497
Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
- 1 December 2015
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 96 (3) , 483-497
Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
- Open Access
- 31 August 2013
- Published by Springer Nature in Genome Medicine
- Vol. 5 (8) , 78
Clinical and molecular characterization of HER2amplified-pancreatic cancer
Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome. Although HER2 amplification occurs in pancreatic cancer, it is inadequately characterized to exploit the potential of anti-HER2 therapies. Methods: HER2 amplification was detected and further analyzed using multiple genomic sequencing approaches. Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with pancreatic ductal adenocarcinoma (PDAC). Results: An amplified inversion event (1 MB) was identified at the HER2 locus in a patient with PDAC. Using standardized laboratory assays, we established diagnostic criteria for HER2 amplification in PDAC, and observed a prevalence of 2%. Clinically, HER2- amplified PDAC was characterized by a lack of liver metastases, and a preponderance of lung and brain metastases. Excluding breast and gastric cancer, the incidence of HER2-amplified cancers in the USA is >22,000 per annum. Conclusions: HER2 amplification occurs in 2% of PDAC, and has distinct features with implications for clinical practice. The molecular heterogeneity of PDAC implies that even an incidence of 2% represents an attractive target for anti-HER2 therapies, as options for PDAC are limited. Recruiting patients based on HER2 amplification, rather than organ of origin, could make trials of anti-HER2 therapies feasible in less common cancer types.
- 31 August 2013
- Published by Springer Nature in Genome Medicine
- Vol. 5 (8) , 78
Open AccessClinical and molecular characterization of HER2amplified-pancreatic cancer
Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome. Although HER2 amplification occurs in pancreatic cancer, it is inadequately characterized to exploit the potential of anti-HER2 therapies. Methods: HER2 amplification was detected and further analyzed using multiple genomic sequencing approaches. Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with pancreatic ductal adenocarcinoma (PDAC). Results: An amplified inversion event (1 MB) was identified at the HER2 locus in a patient with PDAC. Using standardized laboratory assays, we established diagnostic criteria for HER2 amplification in PDAC, and observed a prevalence of 2%. Clinically, HER2- amplified PDAC was characterized by a lack of liver metastases, and a preponderance of lung and brain metastases. Excluding breast and gastric cancer, the incidence of HER2-amplified cancers in the USA is >22,000 per annum. Conclusions: HER2 amplification occurs in 2% of PDAC, and has distinct features with implications for clinical practice. The molecular heterogeneity of PDAC implies that even an incidence of 2% represents an attractive target for anti-HER2 therapies, as options for PDAC are limited. Recruiting patients based on HER2 amplification, rather than organ of origin, could make trials of anti-HER2 therapies feasible in less common cancer types.
- 24 June 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6
Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer
- 24 June 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6
Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer